Lisanti Capital Growth’s Sarepta Therapeutics SRPT Stock Holding History

Lisanti Capital Growth’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,400	Closed	-$1.83M	–	143
2020 Q2	$1.83M	Buy	11,400 +4,868	+75%	+$662K	0.37%	93
2020 Q1	$639K	Buy	+6,532	New	+$747K	0.21%	99
2019 Q1	–	Sell	-9,350	Closed	-$1.02M	–	129
2018 Q4	$1.02M	Buy	9,350 +2,030	+28%	+$254K	0.41%	77
2018 Q3	$1.18M	Sell	7,320 -1,420	-16%	-$194K	0.41%	90
2018 Q2	$1.16M	Sell	8,740 -22,780	-72%	-$2.15M	0.44%	85
2018 Q1	$2.33M	Buy	31,520 +11,215	+55%	+$748K	1.13%	35
2017 Q4	$1.13M	Buy	20,305 +9,085	+81%	+$481K	0.65%	70
2017 Q3	$509K	Buy	+11,220	New	+$448K	0.32%	98
2016 Q4	–	Sell	-5,405	Closed	-$332K	–	105
2016 Q3	$332K	Buy	+5,405	New	+$163K	0.42%	89

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lisanti Capital Growth's SRPT Position: Q3 2020 in Review

Lisanti Capital Growth sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 11,400 shares — an estimated $1.83M sold.

Lisanti Capital Growth first reported a position in SRPT in Q3 2016 and held it in 9 quarters. The position peaked at $2.33M in Q1 2018. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

Lisanti Capital Growth reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
Lisanti Capital Growth sold 11,400 Sarepta Therapeutics shares in Q3 2020, an estimated $1.83M.
Lisanti Capital Growth first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 9 quarters.
Lisanti Capital Growth's Sarepta Therapeutics position peaked at $2.33M in Q1 2018.
403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Lisanti Capital Growth's 13F filing for Q3 2020, filed 5 Nov 2020.